22 results about "Solid lipid nanoparticle" patented technology

The invention discloses a solid lipid nanoparticle-inulin gel compound for targeted therapy of ulcerative colitis and a preparation method of the solid lipid nanoparticle-inulin gel compound, and belongs to the technical field of medicines, the compound comprises inulin gel and solid lipid nanoparticles dispersed in the inulin gel; the solid lipid nanoparticle comprises a glyceride shell, oleic acid coated by the glyceride shell, a medicine with anti-inflammatory and anti-oxidation effects, and cationic lipid, the mass ratio of the oleic acid to the medicine with the anti-inflammatory and anti-oxidation effects to the cationic lipid is 1: (1-1.5): (2.5-3); the drug loading capacity in the solid lipid nanoparticles is 1 to 10 weight percent. According to the compound, the inulin gel serves as a delivery system, functional solid lipid nanoparticles are carried in the compound, intestinal ferroptosis can be reduced, active oxygen can be removed, the compound has the effects of promoting intestinal barrier repair, relieving inflammatory response and the like, and the compound has good application prospects in the aspect of treatment of ulcerative colitis.

A system for the production of fenoprofen calcium-loaded solid lipid nanoparticles, comprising units for organic phase production, emulsification, homogenization and solvent extraction, configured to produce nanoparticles with controlled size and encapsulation efficiency.

The granulator comprises a machine body and a bearing plate, the bearing plate is installed on one side of the machine body, two sets of electric push rods are installed at the top end of the bearing plate, push arms are installed at the output ends of the electric push rods, a supporting plate is arranged above the electric push rods, and the supporting plate is connected with the bearing plate. The device comprises a supporting plate, the supporting plate is connected with a push arm, a rotating plate is arranged above the supporting plate, a movable shaft is movably installed at the center of the supporting plate and connected with the rotating plate, a driving motor is installed at the bottom end of the supporting plate, a driving shaft is installed at the output end of the driving motor, and the surface of the driving shaft is sleeved with a transmission gear. The surface of the movable shaft on one side of the transmission gear is sleeved with a driven gear. According to the utility model, convenient high-hydraulic-pressure shearing processing of homogenized liquid is realized, the liquid can be conveniently input in sequence, and the liquid homogenizing effect is improved.

The invention discloses a chondroitin sulfate modified dihydromyricetin solid lipid nanoparticle, and belongs to the field of pharmaceutics. The nanoparticle is composed of a solid lipid component, dihydromyricetin encapsulated in the solid lipid component and a chondroitin sulfate targeting ligand modified on the surface. According to the invention, the chondroitin sulfate is specifically combined with the high-expression CD44 receptor on the surface of the hepatic stellate cell, so that the active targeting delivery of the drug to the hepatic fibrosis focus is realized. The nanoparticles have the characteristics of uniform particle size, high encapsulation efficiency and good slow release effect, can significantly improve the enrichment concentration of dihydromyricetin in the liver, enhance the anti-hepatic fibrosis curative effect and reduce the systemic side effects, and have good application prospects in preparation of hepatic fibrosis targeted therapy drugs.

The present application belongs to the technical field of drug delivery, and relates to a sequential multi-stage targeted delivery system of a probiotic and prebiotic combination for repairing intestinal barriers. The delivery system is a microcapsule MP wrapped with NPs; the NPs are solid lipid nanoparticles formed by wrapping a probiotic with hyaluronic acid coupled small molecule acids as a film material; and the shell material of the microcapsule MP is a prebiotic. By wrapping the probiotic with hyaluronic acid coupled small molecule acids as a film material to form NPs, and then wrapping the NPs with a prebiotic wall material to form a microcapsule, the sequential multi-stage targeting and zonal release of different drugs can be achieved; the repair of the barrier will not have a reverse effect; the intestinal epithelial cell proliferation is promoted to repair the mechanical barrier; the intestinal flora abundance is improved to repair the microbial barrier; the mucus secretion is promoted to repair the chemical barrier; and the immune homeostasis is regulated to repair the immune barrier.

To provide formulated and / or co-formulated liposomal compositions containing TFG β antagonist prodrugs useful in the treatment of cancer, and methods thereof.SOLUTION: Disclosed herein are formulated and / or co-formulated liposomes (LNPs) and solid lipid nanoparticles (SLNPs) comprising TB prodrugs, and methods of making said LNPs and SLNPs. TB pro-drug compositions comprise a drug moiety, a lipidic moiety, and a linking unit, and inhibit ALK5. TB prodrugs can be formulated and / or co-formulated into liposomes or solid lipid nanoparticles to provide a method of treating cancer, immunological disorders, and other diseases by utilizing a targeted drug delivery vehicle.SELECTED DRAWING: None

Disclosed is a process for the assembly modified solid lipid nanoparticles (m-SLNs) by a process that comprises: (i) (a) a therapeutic amount of one or more psychedelics, (b) a solid lipid at room temperature (25 °C) that can be composed of mono-, di, and tri- glycerides, (c) a primary surfactant, (d) optionally, one or more co-surfactant(s), (e) optionally, the addition of a liquid lipid at room temperature (25 °C), (f) optionally, the incorporation of a targeting moiety for a target receptor to initiate a physiological response. For the species to be considered a m-SLN, it must incorporate component (e) and / or component (f). (ii) high-shear mixing said ingredients in a container to form a coarse suspension product, and (iii) subjecting the coarse suspension through a microfluidic device to produce a modified solid lipid nanoparticle containing a psychedelic(s)

Disclosed is a process for the assembly solid lipid nanoparticles (SLNs) by a process that comprises: (a) combining (i) a therapeutic amount of one or psychedelics, (ii) a solid lipid at room temperature (25 °C) that can be composed of mono-, di, and tri-glycerides, (iii) a primary surfactant, (iv) a co-surfactant(s) (b) high-shear mixing said ingredients in a container to form a coarse-emulsion product, and (c) subjecting the coarse-emulsion through a microfluidic device to produce a solid lipid nanoparticle nanoemulsion containing a psychedelic(s).

Disclosed is a process for the assembly solid lipid nanoparticles by a process that comprises: mixing (i) a therapeutic amount of one or more psychedelic agents, (ii) a protein-based drug carrier using desolvation under high-shear mixing conditions to form a coarse-sized particulate product, and passing the coarse-sized particulate product through a microfluidic device under high shear conditions to produce a protein-based drug nanocarrier containing the one or more psychedelic agents.

The application provides a kind of construction and application of multi-stage targeted carrier of viral antigen and adjuvant.It is a kind of nanometer loading SARS-CoV-2 and other viral recombinant protein antigens and vaccine adjuvant Toll-like receptor agonists by using liposome, solid lipid nanoparticle, nanoemulsion, polymer micelle and nanocapsule, etc., the surface of the nanocarrier is modified by using mannose and cationic peptide Par, and the nanocarrier is endowed with multi-stage targeting of dendritic cells and endoplasmic reticulum.By adjusting the ratio of Man and Par, the processing of SARS-CoV-2 and other viral recombinant protein antigens in the endoplasmic reticulum and lysosome of DC cells can be effectively regulated, the presentation of exogenous antigens by DC cells is enhanced, and the initiation of CD8+ and CD4+ T cells in the body is promoted; meanwhile, the nanocarrier can also deliver very low dose of CpG-OND adjuvant directly to the endoplasmic reticulum of DC cells to play a role, and the potential immunotoxicity induced by the adjuvant is reduced.

Disclosed herein are formulated and / or co-formulated liposomes, lipid nanoparticles (LNPs), and solid lipid nanoparticles (SLNPs) comprising a TB prodrug, as well as methods of making the LNPs and the SLNPs. The TB prodrug composition includes a drug moiety, a lipid moiety, and a linking unit that inhibits ALK5. The TB prodrugs may be formulated and / or co-formulated into nanocarriers to provide methods of treating cancer, immune disorders, and other diseases by utilizing targeted drug delivery vehicles.

A particle includes at least one or more kinds of substrate and lipid nanoparticles. The lipid nanoparticles are dispersed in the substrate and contain a physiologically active substance. The lipid nanoparticles are one or more kinds selected from liposomes, lipid emulsions, and solid lipid nanoparticles. A corresponding powder inhalant contains the particle. A production method for the particle includes granulating and drying, in which a suspension containing the substrate and the lipid nanoparticles are granulated and dried in a gas medium.

The invention discloses sinomenine hydrochloride solid lipid nanoparticles, gel, a preparation method and application, by exploring the preparation method of the sinomenine hydrochloride solid lipid nanoparticles HA-SH-SLNs, when the mass ratio of sinomenine hydrochloride to soya bean lecithin to hyaluronic acid modified targeting molecule DSPE-PEG-HA to poloxamer Pluronic F-68 is (0.3-0.7): (1-4): (0.0125-0.1): (1-4), the gel can be used for preparing the sinomenine hydrochloride solid lipid nanoparticles HA-SH-SLNs. The sinomenine hydrochloride solid lipid nanoparticles which are uniform in particle size, high in encapsulation efficiency, high in drug loading capacity and stable in quality are obtained, and the preparation method of the sinomenine hydrochloride solid lipid nanoparticle gel is further researched. The obtained sinomenine hydrochloride solid lipid nanoparticle gel HA-SH-SLNs-Gel is good in stability and small in hemolysis rate, the in-vivo residence time is longer than that of sinomenine hydrochloride solid lipid nanoparticles, the drug release period is delayed, and better articular cavity injection administration is facilitated.

The present invention relates to a genetic material carrier for transdermal delivery and a composition for preventing or treating cancer, comprising same. The genetic material carrier according to the present invention can promote the transdermal delivery of a genetic material and target cancer cells and has appropriate nano-size distribution and minimum non-specific cytotoxicity, by coating, with hyaluronic acid (HA), cationic solid lipid nanoparticles (CSLNs) that carry angiogenesis-inhibiting siVEGF, and thus can be used as a novel transdermal drug carrier for targeted cancer therapy.

This invention relates to liposomes having mucopenetrating action and rates of incorporation of a retinoid, for example retinoic acid (RA), greater than those obtained in solid lipid nanoparticles (0.1%), thus increasing the uptake thereof via the nasal mucosa, and to the method for preparing a liposome. The present invention also relates to an intranasal composition, for example a vaccine, comprising said liposome, which is more effective than existing vaccines, the method for preparing same and the use thereof for preventing illnesses.

Provided herein is a process for preparing solid lipid nanoparticles of curcumin. Also provided herein are solid lipid nanoparticles of curcumin having a particle size in the range of 20-800 nm. The solid lipid nanoparticles of curcumin show a very high entrapment efficiency of curcumin in the range of 50-100% in terms of actual curcumin content of the formulation. The solid lipid nanoparticles of curcumin show increased efficacy of the curcumin.

The present application relates to formulated and / or co-formulated liposome compositions containing TFG [beta] antagonist prodrugs and methods thereof that can be used to treat cancer. Disclosed herein are formulated and / or co-formulated lipid nanoparticles (LNPs) and solid lipid nanoparticles (SLNPs) comprising a TB prodrug and methods of making the LNPs and the SLNPs. The TB prodrug composition comprises a drug part, a lipid part and a connecting unit, and the TB prodrug composition inhibits ALK5. The TB prodrugs may be formulated and / or co-formulated into liposomes or solid lipid nanoparticles to provide methods of treating cancer, immune disorders, and other diseases by utilizing targeted drug delivery vehicles.

The present application relates to ionizable lipid compounds containing borneol structure and its preparation method and application, and belongs to the technical field of biological medicine. The present application introduces polyamine structure and hydrophobic tail chain by modifying the hydroxyl group at C2 position of borneol molecule, and prepares a new type of ionizable lipid compounds containing borneol structure. The compound has the following advantages: (i) the borneol structure can effectively break through the skin keratin layer barrier and significantly improve the transdermal absorption efficiency; (ii) the polyamine structure can be ionized under acidic conditions, efficiently carry nucleic acid drugs through electrostatic adsorption, help to enhance the stability of nucleic acid and promote lysosome escape; (iii) the tail chain modification enhances the liposolubility of the compound, endows it with lipid characteristics, and can be used as a raw material for the preparation of solid lipid nanoparticles. The present application also provides a preparation method of the compound, and the ionizable lipid compounds containing borneol structure show good application prospect in the field of transdermal delivery of nucleic acid drugs.

According to the present invention, it is possible to provide a drug carrier having excellent bioavailability and improved drug encapsulation efficiency by preparing lipoprotein-mimicking solid lipid nanoparticles having a core-shell structure consisting of albumin-conjugated cholesterol, a fusogenic lipid, a cationic lipid, a triglyceride and a cholesteryl ester.

Solid lipid nanoparticles (SLNs) containing (a) a cationic form of lipid SM-102 or a cationic form of lipid ALC-0315, (b) distearoylphosphatidylcholine (DSPC), (c) cholesterol, and (d) an anionic form of a drug containing a phosphate, phenolate, or carboxylate encapsulated in 1,2-dimiristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 or ALC-0159, wherein the anionic form of the drug and the cationic form of lipid (a) form an ionic complex or salt of the solid lipid nanoparticles (SLNs); SLNs containing an anionic form of a drug containing a phosphate, phenolate, or carboxylate encapsulated in dimethyldidodecylammonium bromide or 1,2-dioleoyl-3-trimethylammonium-propane; pharmaceutical compositions containing SLNs; methods for producing SLNs.

The present invention relates to the field of lipid nanoparticles (LNP) and direct delivery of an active agent to a cell. It provides lipid nanoparticle constructs that are particularly useful for delivery of active agents, e.g., of RNA, preferably, mRNA, to cells. The lipid nanoparticle constructs comprise a specific neutral hydrophilic solid lipid nanpoparticle (SLP) and a targeting agent associated with the nanoparticle, e.g. a single domain antibody (sdAb), which may, for example target CD4. The lipid nanoparticle construct may comprise an active agent, and it may be used for targeting a cell such as a T cell. Pharmaceutical compositions comprising the nanoparticle constructs are also provided, in particular for use in targeting a cell. The invention also provides a composition or kit suitable for preparing the lipid nanoparticle construct of the invention.